1. Home
  2. PCRX vs EVMN Comparison

PCRX vs EVMN Comparison

Compare PCRX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$25.10

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

EVMN

Evommune Inc.

N/A

Current Price

$24.11

Market Cap

914.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
EVMN
Founded
2006
2020
Country
United States
United States
Employees
N/A
48
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
914.1M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
EVMN
Price
$25.10
$24.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$30.25
$43.88
AVG Volume (30 Days)
398.4K
251.0K
Earning Date
04-30-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.16
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$6.78
N/A
Revenue Next Year
$8.54
N/A
P/E Ratio
$158.81
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$13.89
52 Week High
$27.64
$33.20

Technical Indicators

Market Signals
Indicator
PCRX
EVMN
Relative Strength Index (RSI) 58.93 44.62
Support Level $20.56 $21.14
Resistance Level $25.23 $25.50
Average True Range (ATR) 0.88 1.80
MACD 0.09 -0.32
Stochastic Oscillator 65.79 13.16

Price Performance

Historical Comparison
PCRX
EVMN

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: